Obesity-Related Asthma Mechanisms and Interventions

Obesity has emerged as a pivotal modifier of asthma by altering both lung mechanics and inflammatory pathways. Excess adipose tissue imposes mechanical loads on the chest wall, reducing lung volume and altering airway calibre. Concurrently, metabolic dysregulation in obesity drives systemic and airway inflammation through elevated adipokines and pro-inflammatory cytokines that reshape immune cell function. This phenotype is often refractory to standard therapies, exhibiting persistent airway hyperresponsiveness and steroid insensitivity. Emerging evidence implicates interactions between metabolic hormones, immune cell subsets and the microbiome in perpetuating airway inflammation. Interventions range from lifestyle-based weight reduction to targeted pharmacotherapies that modulate receptor signalling and restore immunometabolic balance. A nuanced understanding of these mechanisms offers promise for precision therapies tailored to patients with obesity-related asthma, with the potential to alleviate disease burden on a global scale.

Research from Nature Portfolio

Recent studies have illuminated the role of metabolic hormones in airway function. One investigation revealed that cholecystokinin, traditionally known for its role in satiety, is elevated in obese lungs and drives smooth muscle contraction via the cholecystokinin A receptor. Pharmacological blockade of this receptor attenuated airway hyperresponsiveness in obese animal models, suggesting a repurposing opportunity for existing antagonists. Foundational work on microbiome–immune interactions has further shown that obesity amplifies pro-inflammatory signatures and disturbs microbial diversity in asthmatic patients. Restoration of specific gut bacteria, notably Akkermansia muciniphila, reduced airway inflammation and hyperreactivity in preclinical models, highlighting the non-redundant role of microbial communities in this phenotype.

Obesity-Related Asthma Mechanisms and Interventions publication trend

The graph below shows the total number of articles in obesity-related asthma mechanisms and interventions across all publications each year (not limited to Nature Index journals).

Technical terms

Airway hyperresponsiveness: Exaggerated constriction of the airways in response to stimuli, leading to breathing difficulty.

Cholecystokinin: A metabolic hormone that regulates digestion and satiety, here implicated in airway smooth muscle contraction.

Adipokine: A bioactive molecule secreted by fat cells that modulates inflammation and metabolic processes.

Innate lymphoid cells: A family of immune cells that rapidly produce cytokines and contribute to airway inflammation.

Microbiome: The collective community of microorganisms that inhabit the body and influence immune and metabolic homeostasis.

References

1. Antagonizing cholecystokinin A receptor in the lung attenuates obesity-induced airway hyperresponsiveness. Nature Communications (2023).
2. Essential role of Card11 in airway hyperresponsiveness in high-fat diet-induced obese mice. Experimental & Molecular Medicine (2024).
3. Obesity: Next game changer of allergic airway diseases?. Clinical and Translational Medicine (2025).
4. Free fatty acid receptor 4 (FFA4) activation attenuates obese asthma by suppressing adiposity and resolving metaflammation. Biomedicine & Pharmacotherapy (2024).
5. Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. Nature Communications (2019).